Bora Pharmaceuticals Co., Ltd. (TPE:6472)
Taiwan · Delayed Price · Currency is TWD | Market Cap | 53.59B -34.9% |
| Revenue (ttm) | 19.56B +0.3% |
| Net Income | 1.55B -62.0% |
| EPS | 7.84 -72.3% |
| Shares Out | 127.29M |
| PE Ratio | 45.31 |
| Forward PE | 14.57 |
| Dividend | 10.00 (2.38%) |
| Ex-Dividend Date | Jul 31, 2026 |
| Volume | 358,917 |
| Open | 428.00 |
| Previous Close | 428.00 |
| Day's Range | 419.50 - 430.00 |
| 52-Week Range | 330.50 - 671.00 |
| Beta | 0.44 |
| Analysts | Buy |
| Price Target | 575.04 (+36.59%) |
| Est. Earnings | Nov 12, 2026 |
About Bora Pharmaceuticals
Bora Pharmaceuticals Co., Ltd. engages in contract development, manufacture, and sale of pharmaceuticals in Europe, the United States, Taiwan, and internationally. The company operates through Sales, CDMO, and Other segments. It manufactures and sells generic, brand, and over the counter (OTC) drugs. The company also offers contract development and manufacturing services and technical services for the development of pharmaceutical products. In addition, it provides Western pharmaceuticals, including central nervous system medications, antibioti... [Read more]
Full Company ProfileFinancial Performance
In 2025, Bora Pharmaceuticals's revenue was 19.01 billion, an increase of 9.11% compared to the previous year's 17.43 billion. Earnings were 2.98 billion, a decrease of -22.61%.
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for 6472 stock is "Buy." The 12-month stock price target is $575.04, which is an increase of 36.59% from the latest price.
News
Bora Pharmaceuticals Earnings Call Transcript: Q2 2026
Q2 2026 saw a robust rebound with 47% revenue growth quarter-over-quarter, record backlogs, and strong specialty pharma and CDMO performance. The Rockville biologics facility acquisition and Sunway Biotech's Weider deal are set to drive further growth and synergies.
Bora Pharmaceuticals Slides: Q2 2026
Bora Pharmaceuticals has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 13, 2026.
Bora Pharmaceuticals Quarterly report: Q2 2026
Bora Pharmaceuticals has published its Q2 2026 quarterly earnings report on August 13, 2026.
Bora Pharmaceuticals and Onconic Therapeutics Sign Manufacturing Agreement to Support U.S. Clinical Development of JAQBO Tablets
MAPLE GROVE, Minn.--(BUSINESS WIRE)--Bora Pharmaceuticals and Onconic Therapeutics Sign Manufacturing Agreement to Support U.S. Clinical Development of JAQBO Tablets.
Taiwan's Bora Pharmaceuticals in potential $2.5 billion collaboration with Insilico Medicine
Taiwan-based contract drugmaker Bora Pharmaceuticals will partner with Insilico Medicine on a collaboration aimed at improving efficiency, potentially valued at more than $2.5 billion if fully imple...
Insilico Medicine and Bora Pharmaceuticals Announce Strategic Alliance for AI-Driven Drug Discovery and Development
Combines Insilico's Pharma.AI platform with Bora's global development, manufacturing, quality, and commercialization capabilities to explore a next-generation drug innovation model CAMBRIDGE, Mass. an...
Bora Pharmaceuticals Earnings Call Transcript: Q1 2026
Q1 2026 saw a sequential revenue decline due to scheduled maintenance and generics headwinds, but March rebounded and strong order backlog supports a positive outlook. Two major acquisitions—MacroGenics CDMO and Weider Global Nutrition—are set to drive growth and diversify revenue.
Bora Pharmaceuticals Slides: Q1 2026
Bora Pharmaceuticals has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 13, 2026.
Bora Pharmaceuticals Quarterly report: Q1 2026
Bora Pharmaceuticals has published its Q1 2026 quarterly earnings report on May 13, 2026.
Bora Pharmaceuticals Transcript: Life Sciences Virtual Investor Forum
FY2025 saw record revenues, major CDMO contract wins, and expansion into biologics, with specialty pharma now 45% of sales. Investments in U.S. and Taiwan facilities, AI, and ESG initiatives position the company for strong growth in CDMO, biologics, and rare disease markets in 2026.
Bora Pharmaceuticals Slides: Q4 2025
Bora Pharmaceuticals has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on March 10, 2026.
Bora Pharmaceuticals Quarterly report: Q4 2025
Bora Pharmaceuticals has published its Q4 2025 quarterly earnings report on March 10, 2026.
Bora Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference
Significant expansion and operational improvements drove 2025 revenue to $634 million, with a 700% market cap increase since 2017. Strategic U.S. investments, a focus on high-value generics and rare diseases, and strong ESG performance position the company for continued growth.
Bora Pharmaceuticals Slides: 44th Annual J.P. Morgan Healthcare Conference
Bora Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on January 15, 2026.
Bora Pharmaceuticals Earnings Call Transcript: Q3 2025
Record CDMO and specialty pharma growth drove a 15% year-over-year revenue increase and improved margins, despite ongoing integration and external headwinds. Strategic acquisitions, capacity expansions, and a focus on high-value products position the business for continued growth into 2026.
Bora Pharmaceuticals Quarterly report: Q3 2025
Bora Pharmaceuticals has published its Q3 2025 quarterly earnings report on November 13, 2025.
Bora Pharmaceuticals Slides: Q3 2025
Bora Pharmaceuticals has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on November 13, 2025.